News, info and tips for living with multiple sclerosis
I see a lot of reasons why people stop, or refuse to start, an MS medication. “Thinking of stopping the…meds. Sick of the shots and how they hurt to take them” “I stopped all of them….all multiple times. It takes too long for an appointment and I tapered off “ “Half the s**t will kill you” “My body and my choice” “The side effects are worse than the disease” Forty…Continue Reading
How quickly to start a disease-modifying therapy after an MS diagnosis is a question that I frequently see when browsing online. It goes hand in hand with which DMT is best to start with. There are many things to consider when making that decision. Here’s a study that may help you weigh the benefits and risks hitting your MS hard and fast. Any DMT is better than none The study,…Continue Reading
There are more than a dozen disease-modifying therapies available for treating MS. Some are shots, some are infusions, and some are pills. Some are more effective than others. The marketing intelligence company Spherix Global Insights regularly surveys which of these treatments are being used by neurologists and what’s influencing their selection. Here’s what the latest Spherix quarterly survey shows about what’s being prescribed. Just over half of the 100 neurologists…Continue Reading
Over the past few of weeks, warnings have been issued about side effects of two MS treatments. First, the U.S. Food and Drug Administration warned about a “slight” risk of seriously worsening MS symptoms if someone who is using the disease-modifying therapy Gilenya (fingolimod) stops using it. The FDA’s alert said the worsening symptoms could “result in permanent disability,” but the alert failed to provide details about how rare these…Continue Reading
I’ve just passed the second anniversary of my Lemtrada (alemtuzumab) treatment. My first infusion round was the first week of December 2016. Round 2, delayed by four months, was done last April. So, it’s time to update my Lemtrada journey for you. Lemtrada, in case you’re not familiar with this treatment, has been described by some as “HSCT lite.” The medication kills specific B- and T-cells that are thought to play…Continue Reading
MS medications are expensive in the United States. We all know that. We also know that less expensive meds can be found in places like Canada and Mexico. So, here’s a novel idea from the nonprofit health insurance provider PEHP, which covers state workers and their families in Utah: Pay those patients to buy their expensive meds south of the border. As Erin Alberty reports in The Salt Lake Tribune, the…Continue Reading
Many of us have received help to pay for our MS medications. Now it’s possible that patient assistance programs, including copay help, could be threatened. A recent article in the The Wall Street Journal reports that U.S. government prosecutors are looking into whether some pharmaceutical companies’ patient assistance programs are on the wrong side of the law. These include direct copay assistance, donations to foundations that help patients pay for…Continue Reading
Ocrevus (ocrelizumab) is a serious disease-modifying therapy. It has the potential to deliver a major blow to a patient’s multiple sclerosis, but it also carries the possibility of severe side effects. The protocol for Ocrevus requires different doses on different infusion dates, following a specific treatment schedule. It’s also very expensive. This all shouts for the need for serious care coordination! Jamie’s care coordination problems I was concerned when Jamie, who…Continue Reading
MS drugs are expensive. Many people with MS are able to afford their high prices only because their insurance covers most of the cost. Then what remains as a copay has often been covered by the pharmaceutical companies that produce those meds, who have offered patient assistance programs or discount cards to help pay the copay. So, your out-of-pocket costs have been minimal or none. Now, however, that paradigm is…Continue Reading
Two multiple sclerosis medications that are both popular and expensive are on a new “shame list” that U.S. regulators hope will increase price competition. The medications are Ampyra (dalfampridine), made by Acorda, and Tecfidera (dimethyl fumarate), by Biogen. They’re included on a list of more than 50 medications whose manufacturers, according to the Food and Drug Administration, are putting obstacles in front of companies that want to create cheaper, generic versions.…Continue Reading